In April 2016, letters were sent to healthcare professionals regarding:
- canagliflozin-containing medicines (Invokana▼, Vokanamet▼): risk of lower limb amputation (primarily of the toe)
- BCR-ABL tyrosine kinase inhibitors (imatinib▼, dasatinib, nilotinib, bosutinib▼, ponatinib▼) and risk of hepatitis B reactivation: screen patients for hepatitis B virus before treatment - see also article in this issue
- pomalidomide (Imnovid▼): hepatitis B virus status to be established before initiating treatment - see also article in this issue
- retigabine (Trobalt): risk acquired vitelliform maculopathy
Article citation: Drug Safety Update Vol 9 issue 10 May 2016 4.